Skip to content
DataLookout
Menu

NCT04848064

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 30, 2026 to Jul 30, 2027
    • Eligibility criteria expanded, about 4 words
    • Study completion pushed from Jan 30, 2027 to Jul 30, 2028
    • Secondary endpoints: details revised at 4 of 6 entries
  2. Notable Primary completion date: Oct 30, 2025 to Oct 30, 2026
    • Eligibility criteria expanded, about 39 words
    • Study completion date: Jan 30, 2026 to Jan 30, 2027
    v8
  3. Notable Primary completion date: Apr 30, 2025 to Oct 30, 2025
    • Study completion date: Apr 30, 2025 to Jan 30, 2026
    v7
  4. Minor Primary and study completion dates: Dec 31, 2024 to Apr 30, 2025v6
  5. Notable Primary completion date: Dec 31, 2023 to Dec 31, 2024v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date changed from estimate of Nov 1, 2021 to May 6, 2022v4
  2. Notable Eligibility criteria expanded, about 14 wordsv3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 1, 2021 to Nov 1, 2021
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events
Timeframe: Up to day 84

Secondary (6)

Overall response rate (ORR)
Progression free survival
Overall survival
Natural Killer (NK)-cell numerical expansion in vivo
Analysis of cytokine levels
Show 1 moreShow less
Quality of life analysis

Arms and interventions

Treatment (mogamulizumab, chemotherapy, NK cells)Experimental

Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.

Drugs: Cyclophosphamide, Fludarabine

Biologicals: Mogamulizumab, Natural Killer Cell Therapy

Other: Quality-of-Life Assessment, Questionnaire Administration

Sites

1 site in 1 country

  • Ohio State University Comprehensive Cancer CenterColumbus, Ohio, United States